Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent (dupilumab) improved moderate-to-severe asthma

14:17 EDT 21 May 2018 | FinanzNachrichten

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent (dupilumab) improved moderate-to-severe asthma Resul...

More From BioPortfolio on "Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent (dupilumab) improved moderate-to-severe asthma"